RU2018147430A3 - - Google Patents

Download PDF

Info

Publication number
RU2018147430A3
RU2018147430A3 RU2018147430A RU2018147430A RU2018147430A3 RU 2018147430 A3 RU2018147430 A3 RU 2018147430A3 RU 2018147430 A RU2018147430 A RU 2018147430A RU 2018147430 A RU2018147430 A RU 2018147430A RU 2018147430 A3 RU2018147430 A3 RU 2018147430A3
Authority
RU
Russia
Application number
RU2018147430A
Other languages
Russian (ru)
Other versions
RU2743163C2 (ru
RU2018147430A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018147430A3 publication Critical patent/RU2018147430A3/ru
Publication of RU2018147430A publication Critical patent/RU2018147430A/ru
Application granted granted Critical
Publication of RU2743163C2 publication Critical patent/RU2743163C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2018147430A 2016-06-10 2017-06-09 Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их RU2743163C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655392 2016-06-10
FR1655392A FR3052452B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2017/064067 WO2017212012A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
RU2018147430A3 true RU2018147430A3 (enExample) 2020-07-10
RU2018147430A RU2018147430A (ru) 2020-07-10
RU2743163C2 RU2743163C2 (ru) 2021-02-15

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018147430A RU2743163C2 (ru) 2016-06-10 2017-06-09 Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их

Country Status (46)

Country Link
US (1) US11046681B2 (enExample)
EP (1) EP3468974B1 (enExample)
JP (1) JP6928005B2 (enExample)
KR (1) KR20190016106A (enExample)
CN (1) CN109311888B (enExample)
AR (1) AR108706A1 (enExample)
AU (1) AU2017277734B2 (enExample)
BR (1) BR112018075433A2 (enExample)
CA (1) CA3027014C (enExample)
CL (1) CL2018003474A1 (enExample)
CO (1) CO2018013210A2 (enExample)
CR (1) CR20180564A (enExample)
CU (1) CU20180145A7 (enExample)
CY (1) CY1122870T1 (enExample)
DK (1) DK3468974T3 (enExample)
DO (1) DOP2018000270A (enExample)
EA (1) EA037211B1 (enExample)
EC (1) ECSP18090144A (enExample)
ES (1) ES2775789T3 (enExample)
FR (1) FR3052452B1 (enExample)
GE (1) GEP20207160B (enExample)
HR (1) HRP20200361T1 (enExample)
HU (1) HUE049507T2 (enExample)
IL (1) IL263463B (enExample)
LT (1) LT3468974T (enExample)
MA (1) MA45222B1 (enExample)
MD (1) MD3468974T2 (enExample)
ME (1) ME03670B (enExample)
MX (1) MX374794B (enExample)
MY (1) MY196562A (enExample)
NI (1) NI201800132A (enExample)
NZ (1) NZ748946A (enExample)
PE (1) PE20220567A1 (enExample)
PH (1) PH12018502515B1 (enExample)
PL (1) PL3468974T3 (enExample)
PT (1) PT3468974T (enExample)
RS (1) RS60029B1 (enExample)
RU (1) RU2743163C2 (enExample)
SG (1) SG11201810629QA (enExample)
SI (1) SI3468974T1 (enExample)
SV (1) SV2018005791A (enExample)
TN (1) TN2018000410A1 (enExample)
TW (1) TWI620750B (enExample)
UA (1) UA123794C2 (enExample)
UY (1) UY37288A (enExample)
WO (1) WO2017212012A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR20200094176A (ko) 2017-11-29 2020-08-06 르 라보레또레 쎄르비에르 유비퀴틴 특이적 프로테아제 7의 억제제로서 신규한 피페리디닐 유도체
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
CN112955142A (zh) 2018-09-21 2021-06-11 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
US20220033397A1 (en) * 2018-12-06 2022-02-03 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378807A (zh) * 2005-12-21 2009-03-04 先灵公司 H3拮抗剂/反相激动剂与食欲抑制剂的组合
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
TWI770525B (zh) * 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
CU20180146A7 (es) * 2016-06-10 2019-07-04 Servier Lab Compuestos derivados de (piperidin-1-ilo)(piperidin-4-ilo) sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
CY1122870T1 (el) 2021-05-05
EA037211B1 (ru) 2021-02-19
ECSP18090144A (es) 2019-01-31
ES2775789T3 (es) 2020-07-28
UA123794C2 (uk) 2021-06-02
UY37288A (es) 2018-01-02
CN109311888A (zh) 2019-02-05
ME03670B (en) 2020-10-20
PH12018502515B1 (en) 2021-11-10
AU2017277734A1 (en) 2018-12-20
KR20190016106A (ko) 2019-02-15
MY196562A (en) 2023-04-19
CR20180564A (es) 2019-03-04
IL263463B (en) 2021-01-31
CO2018013210A2 (es) 2018-12-28
JP2019517556A (ja) 2019-06-24
HUE049507T2 (hu) 2020-09-28
HRP20200361T1 (hr) 2020-06-12
DK3468974T3 (da) 2020-05-11
LT3468974T (lt) 2020-04-10
EA201892838A1 (ru) 2019-06-28
FR3052452B1 (fr) 2018-06-22
GEP20207160B (en) 2020-10-12
TN2018000410A1 (en) 2020-06-15
MA45222A (fr) 2019-04-17
PT3468974T (pt) 2020-03-25
TW201802092A (zh) 2018-01-16
TWI620750B (zh) 2018-04-11
IL263463A (en) 2019-01-31
SG11201810629QA (en) 2018-12-28
FR3052452A1 (enExample) 2017-12-15
SI3468974T1 (sl) 2020-07-31
AU2017277734B2 (en) 2021-07-01
MX374794B (es) 2025-03-06
RU2743163C2 (ru) 2021-02-15
CA3027014C (en) 2021-01-05
CA3027014A1 (en) 2017-12-14
CN109311888B (zh) 2021-09-14
US20190144448A1 (en) 2019-05-16
NI201800132A (es) 2019-04-08
EP3468974B1 (en) 2020-02-12
PL3468974T3 (pl) 2020-07-13
CL2018003474A1 (es) 2019-05-24
EP3468974A1 (en) 2019-04-17
RS60029B1 (sr) 2020-04-30
PE20220567A1 (es) 2022-04-13
CU20180145A7 (es) 2019-07-04
PH12018502515A1 (en) 2019-09-30
AR108706A1 (es) 2018-09-19
MD3468974T2 (ro) 2020-05-31
WO2017212012A1 (en) 2017-12-14
MX2018015216A (es) 2019-04-25
RU2018147430A (ru) 2020-07-10
US11046681B2 (en) 2021-06-29
JP6928005B2 (ja) 2021-09-01
BR112018075433A2 (pt) 2019-03-19
SV2018005791A (es) 2019-01-16
MA45222B1 (fr) 2020-04-30
NZ748946A (en) 2025-06-27
DOP2018000270A (es) 2019-05-15

Similar Documents

Publication Publication Date Title
CH714036A1 (enExample)
RU2018147430A3 (enExample)
CN303538480S (enExample)
CN303538548S (enExample)
CN303693353S (enExample)
CN303676199S (enExample)
CN303671773S (enExample)
CN303670798S (enExample)
CN303669564S (enExample)
CN303617151S (enExample)
CN303611618S (enExample)
CN303604001S (enExample)
CN303573485S (enExample)
CN303568454S (enExample)
CN303563311S (enExample)
CN303551478S (enExample)
CN303551471S (enExample)
CN303542236S (enExample)
CN303540828S (enExample)
CN303538830S (enExample)
CN303538789S (enExample)
CN303538766S (enExample)
CN303538750S (enExample)
CN303538741S (enExample)
CN303538725S (enExample)